U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT06954428) titled 'Clinical Trial of Intranasal Delivery of NT-301' on March 07.
Brief Summary: The purpose of this research project is to investigate the safety and tolerability of an approved drug (Apomorphine) when administered as a nasal powder spray formulation (NT-301) as well as collect information on how NT-301 moves into, through and out of your body, called Pharmacokinetics. The study also aims to compare the safety, tolerability and pharmacokinetics of NT-301 to an injectable Apomorphine product (Movapo Pen), already approved for use in Australia.
Study Start Date: April 20
Study Type: INTERVENTIONAL
Condition:
Tolerability of NT-301 Nasa...